Market
Overview:
Gastrointestinal (GI) drugs are medications used to
treat gastrointestinal problems such as heartburn caused by gastroesophageal
reflux disease (GERD), Peptic ulcers that often occur due to certain
medications used in lupus treatment, including NSAIDs and steroids. Chronic GI
complication affects stomach, large intestine, and rectum, small intestine,
esophagus, liver, gallbladder, and pancreas, showing the symptoms such as
heartburn, indigestion, bloating, and constipation among others.
Get
a Free Sample @
https://www.marketresearchfuture.com/sample_request/558
The World Gastroenterology Organization recently
reported that currently, around 35-40 % of the world’s total population is
suffering from acute or Chronic GI complications. These highly prevailing GI
complications create a vast demand for Gastrointestinal Drugs. As a result, the
market for GI drugs is growing pervasively. Over the past few years, many
breakthrough drug discoveries have taken places which are escalating the GI
drugs market on the global heights.
Acknowledging the increasing market size of the market,
Market Research Future (MRFR) in its recently published study report asserts
that the global Gastrointestinal
Drugs Market will register approximately 4.8% CAGR during the forecast
period (2017-2023), reaching USD 59.3 BN by the end of 2023.
The emergence of novel medications accounts for a key
driving force behind the market growth, offering efficient outcomes. Moreover,
several risk factors causing GI complications such as the extensive use of
antibiotics, sedentary lifestyle, and change in dietary pattern among others
foster the market growth. Additionally, smoking, alcohol, use of anticoagulants
or corticosteroids, general health, and length of NSAID therapy also
commutatively contribute to the market growth, increasing the incidence of GI
issues.
Key
Players:
Johnson
(US), Abbott Laboratories(US), Valeant (US), Allergan Plc (US), Janssen Biotech
Inc. (US), Bayer AG (Germany), Takeda Pharmaceutical Company Limited (Japan),
Valeant Pharmaceuticals (US), Eisai Co., Ltd. (Japan), Sanofi (France),
GlaxoSmithKline Plc. (UK), and Boehringer Ingelheim GmbH (Germany).
Global Gastrointestinal Drugs Market – Competitive
Analysis
Drug manufacturers bank on breakthrough discoveries,
collaborating and forming partnerships with the players in medical technology
to develop new manufacturing methods and inventions. The highly competitive
gastrointestinal drugs market appears to be fragmented owing to the several big
and small players along with the new entrants churning the competition in the
market. Key market players are focusing on optimized situational awareness for
customers, ensuring their mission success.
They increasingly invest in R&D activities and
possess state of the art labs and production units along with the strong sales
and distribution network. Marketers operating in the industry are focusing on
inbound lead generation more than ever, looking for ROI-oriented strategies
that can pay off quickly.
Global
Gastrointestinal Drugs Market – Segments:
MRFR has segmented its analysis into five key dynamics for an easy
grasp;
By Drug Categories : Acid Neutralizers (Antacids, H2 antagonists, Proton
pump inhibitors and others), Laxatives & Antidiarrheal, Anti-inflammatory
drugs, and Antiemetic among other.
By Routes of Administration : Oral, Parenteral, and Rectal among other.
By Disease Types : Inflammatory Bowel Disease and Gastroesophageal
Reflux Disease among other.
By End-users : Hospital Pharmacies, and Retail Pharmacies among
other.
By
Regions : North America,
Europe, APAC and the Rest-of-the-World.
Global Gastrointestinal Drugs Market – Regional
Analysis
The North American region accounts for the leading
market for gastrointestinal drugs, followed by Europe and the Asia Pacific,
respectively. North America being a
well-developed region has an edge over other regions in terms of
pharmaceuticals and medical technology. With its highest GDP and hence, the
highest healthcare expenditures the region has a well-established healthcare
sector providing the best medication and quality care.
Factors such as the huge patient pool suffering from
gastrointestinal problems, especially heartburn caused by gastroesophageal
reflux disease (GERD) and Peptic ulcers among others, development in medical
technology, and the presence of key pharma companies in the region are
supporting the growth of the market.
Countries such as the U.S. and Canada, backed by the increasing
prevalence of gastrointestinal issues among people contribute to the market
growth in region to an extent.
Access
Full Report Details @ https://www.marketresearchfuture.com/reports/gastrointestinal-drugs-market-558
The European region is the world’s second-largest
market for gastrointestinal drugs, following the North American market closely.
Factors predominantly driving the market growth include the availability of
effective medications, proliferating healthcare infrastructure providing
quality care, funding support from public and private sectors for R&D of
drug discovery, and a huge patient pool suffering from gastrointestinal
disorders.
Certainly, the resurging economy is a key force driving
the market growth in the region, allowing access to the quality medication and
hence, a great care. Countries such as the UK, Germany, and France with the
breakthrough drug discoveries and burgeoning pharmaceutical industry contribute
to the growth of the regional market significantly. Heading with the augmenting
demand for the gastrointestinal drugs, the region is projected to create a
larger revenue pocket in the global market by 2027.
The Asia Pacific region is rapidly emerging as one of
the promising markets for gastrointestinal drugs, globally. Due to the burgeoning pharma sector the
region is expected to witness a spurting growth over the projected period.
Increasing healthcare expenditures along with the favorable government policies
of some of the developing economies such as India and China support the market
growth in APAC largely.
Browse
Reports Details @ https://www.marketresearchfuture.com/reports/gastrointestinal-drugs-market-558
Furthermore, the unmet clinical needs, availability of
cost-competitive logistic required for the manufacturing of medicines, such as
land, feedstock, and the labour force in the region attracts foreign investors
and encourages drug manufacturers to shift their production bases in the
developing economies such India, and China, which in turn, foster the market growth in the APAC.
Industry/
Innovation/ Related News:
October
17, 2018 – The Gastrointestinal Drugs Advisory Committee of the
US Food and Drug Administration (FDA) approved the recommended reintroduction
of Tegaserod Maleate (Zelnorm, Sloan Pharma) for the treatment of irritable
bowel syndrome with constipation (IBS-C) in women without a history of
cardiovascular (CV) ischemic disease and who have no more than one risk factor
for CV disease.
No comments:
Post a Comment